# FAvipiravir and HydroxyChloroquine Combination Therapy

> **NCT04392973** · NA · COMPLETED · sponsor: **King Abdullah International Medical Research Center** · enrollment: 268 (actual)

## Conditions studied

- COVID19

## Interventions

- **COMBINATION_PRODUCT:** Favipiravir and Hydroxychloroquine

## Key facts

- **NCT ID:** NCT04392973
- **Lead sponsor:** King Abdullah International Medical Research Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-21
- **Primary completion:** 2021-01-26
- **Final completion:** 2021-04-26
- **Target enrollment:** 268 (ACTUAL)
- **Last updated:** 2021-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04392973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04392973, "FAvipiravir and HydroxyChloroquine Combination Therapy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04392973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*